The present invention provides an isolated binding reagent that specifically binds to a recombinant Cocoa Swollen Shoot Virus (CSSV) coat protein antigen having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2 or 4 and/or at least 80% sequence identity to the nucleotide sequence of SEQ ID NO: 1 or 3. A porous membrane based sensor for detecting CSSV comprising a recombinant CSSV coat protein antigen and a method for detecting CSSV using the sensor are also provided. A competitive ELISA for detecting viral infections in plants is also provided.

The present disclosure is directed to human antibodies binding to and neutralizing ebolavirus and methods for use thereof. A further embodiment involves a monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences. In yet another embodiment, there is provided a hybridoma or engineered cell encoding an antibody or antibody fragment. An additional embodiment comprises a vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences. In still a further embodiment, there is provided a method of protecting the health of a placenta and/or fetus of a pregnant a subject infected with or at risk of infection with ebolavirus comprising delivering to said subject the antibody or antibody fragment.

A ribozyme comprising a target-binding domain, a polynucleotide encoding the same, a kit comprising the same, and uses thereof.

A peptide that specifically binds to norovirus, which is useful for detection and infection control of norovirus is provided. A norovirus-binding peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 327.

Provided is a peptide that specifically binds to norovirus, which is useful for detection and infection control of norovirus. A norovirus-binding peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 185.

This disclosure provides novel neutralizing anti-SARS-CoV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-CoV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-CoV-2 infections.

In one embodiment, a method is provided comprising analyte testing on one or more types of samples.

The disclosure relates to particle-based assays for the detection of analytes. Using various combinations of particular technologies, including gold nanorods, silver nanoparticles, gold/silver nanoshells, gold/silver nanocages and nanobubble detection, enhanced detection limits can be achieved across a large range of analytes.

A method and apparatus for comfortably, rapidly, and inexpensively collecting a sample from one or more test subjects and analyzing it, singly or pooled with other samples, for presence of SARS-CoV-2. Saliva, nasal drainage, or other body fluids may be collected from one or more test subjects and examined by means of fluorimetry. Mass rapid screening for SARS-CoV-2 is a valuable public health tool to reduce the transmission of COVID-19 while permitting business activity to resume.

Some embodiments provided herein relate to combined assays. In some embodiments, an assay for identifying influenza type A or influenza type B is combined with an assay for determining the sensitivity of an influenza neuraminidase to an antiviral drug.